94 related articles for article (PubMed ID: 3765649)
1. [Sequential determination of circulating immune complexes in ovarian tumors].
Beaufort F; Auner H; Lahousen M
Wien Med Wochenschr; 1986 Jul; 136(13):317-22. PubMed ID: 3765649
[TBL] [Abstract][Full Text] [Related]
2. Acute phase reactants and circulating immune complexes in patients with ovarian carcinoma.
Dobryszycka W; Gerber J; Zuwała-Jagiełło J; Ujec M
Arch Immunol Ther Exp (Warsz); 1991; 39(1-2):41-50. PubMed ID: 1725104
[TBL] [Abstract][Full Text] [Related]
3. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
5. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
6. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
8. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
[TBL] [Abstract][Full Text] [Related]
10. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
Low JJ; Perrin LC; Crandon AJ; Hacker NF
Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
[TBL] [Abstract][Full Text] [Related]
11. A sequential study of humoral factors in ovarian neoplasms.
Gupta SC; Agarwal J; Singh PA; Mehdiratta NK; Keswani NK
Indian J Pathol Microbiol; 1994 Jul; 37(3):319-26. PubMed ID: 7814065
[TBL] [Abstract][Full Text] [Related]
12. [The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
Zaucha R; Kobierska A
Przegl Lek; 1995; 52(2):51-3. PubMed ID: 7784616
[TBL] [Abstract][Full Text] [Related]
13. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
Skirnisdottir I; Nordqvist S; Sorbe B
Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
[TBL] [Abstract][Full Text] [Related]
14. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
15. Isolated lymph node relapse of epithelial ovarian carcinoma: outcomes and prognostic factors.
Blanchard P; Plantade A; Pagès C; Afchain P; Louvet C; Tournigand C; de Gramont A
Gynecol Oncol; 2007 Jan; 104(1):41-5. PubMed ID: 16952391
[TBL] [Abstract][Full Text] [Related]
16. TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.
Harłozinska A; Sedlaczek P; Van Dalen A; Rozdolski K; Einarsson R
Anticancer Res; 1997; 17(6D):4473-8. PubMed ID: 9494553
[TBL] [Abstract][Full Text] [Related]
17. Pseudomyxoma peritonei: a review of 23 cases.
Wertheim I; Fleischhacker D; McLachlin CM; Rice LW; Berkowitz RS; Goff BA
Obstet Gynecol; 1994 Jul; 84(1):17-21. PubMed ID: 8008316
[TBL] [Abstract][Full Text] [Related]
18. Granulosa cell tumors of the ovary: prognostic factors and outcome.
Malmström H; Högberg T; Risberg B; Simonsen E
Gynecol Oncol; 1994 Jan; 52(1):50-5. PubMed ID: 8307501
[TBL] [Abstract][Full Text] [Related]
19. [Surgical therapy of ovarian carcinoma].
Sevelda P
Wien Med Wochenschr; 1996; 146(1-2):18-22. PubMed ID: 8835491
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]